Orthopedic Arthroscopic Surgery International (O.A.S.I.) Bioresearch Foundation, Gobbi N.P.O., 20133 Milan, Italy.
Department of Orthopaedics and Trauma Surgery, Provincial Polyclinical Hospital, 87100 Torun, Poland.
Int J Mol Sci. 2021 May 23;22(11):5492. doi: 10.3390/ijms22115492.
Knee osteoarthritis (KOA) represents a clinical challenge due to poor potential for spontaneous healing of cartilage lesions. Several treatment options are available for KOA, including oral nonsteroidal anti-inflammatory drugs, physical therapy, braces, activity modification, and finally operative treatment. Intra-articular (IA) injections are usually used when the non-operative treatment is not effective, and when the surgery is not yet indicated. More and more studies suggesting that IA injections are as or even more efficient and safe than NSAIDs. Recently, research to improve intra-articular homeostasis has focused on biologic adjuncts, such as platelet-rich plasma (PRP). The catabolic and inflammatory intra-articular processes that exists in knee osteoarthritis (KOA) may be influenced by the administration of PRP and its derivatives. PRP can induce a regenerative response and lead to the improvement of metabolic functions of damaged structures. However, the positive effect on chondrogenesis and proliferation of mesenchymal stem cells (MSC) is still highly controversial. Recommendations from in vitro and animal research often lead to different clinical outcomes because it is difficult to translate non-clinical study outcomes and methodology recommendations to human clinical treatment protocols. In recent years, significant progress has been made in understanding the mechanism of PRP action. In this review, we will discuss mechanisms related to inflammation and chondrogenesis in cartilage repair and regenerative processes after PRP administration in in vitro and animal studies. Furthermore, we review clinical trials of PRP efficiency in changing the OA biomarkers in knee joint.
膝关节骨关节炎(KOA)代表了一个临床挑战,因为软骨损伤的自发愈合潜力较差。KOA 有多种治疗选择,包括口服非甾体抗炎药、物理治疗、支具、活动修改,最后是手术治疗。当非手术治疗无效且尚未进行手术时,通常会使用关节内(IA)注射。越来越多的研究表明,IA 注射与 NSAIDs 一样有效且安全。最近,改善关节内内稳态的研究集中在生物佐剂上,如富含血小板的血浆(PRP)。膝关节骨关节炎(KOA)中存在的分解代谢和炎症性关节内过程可能会受到 PRP 及其衍生物的影响。PRP 可以诱导再生反应,并改善受损结构的代谢功能。然而,其对间充质干细胞(MSC)的软骨生成和增殖的积极影响仍然存在很大争议。体外和动物研究的建议经常导致不同的临床结果,因为很难将非临床研究结果和方法建议转化为人类临床治疗方案。近年来,人们对 PRP 作用机制的理解取得了重大进展。在这篇综述中,我们将讨论 PRP 给药后在软骨修复和再生过程中与炎症和软骨生成相关的机制,以及在体外和动物研究中。此外,我们还回顾了 PRP 对改变膝关节 OA 生物标志物的有效性的临床试验。